Why Your Weight Loss Stalled on a GLP-1 (And What Actually Helps)

Most people plateau somewhere between month 9 and month 18, and the clinical trials show this clearly. In STEP 5, participants taking semaglutide 2.4 mg lost weight steadily for about 60 weeks, reached an average of 15.2% below starting weight, and then held roughly flat through the end of the two-year study (Garvey et al., Nature Medicine 2022). In SURMOUNT-1, tirzepatide curves were still declining slightly at 72 weeks but had clearly flattened compared with the first six months (Jastreboff et al., NEJM 2022).

That shape is the normal shape. Weight loss on any intervention follows a curve, not a line. The steep part is the first four to six months, when appetite suppression is most novel and your body is largest. The flat part is what happens when the calorie deficit closes on its own.

Why it closes: a smaller body burns fewer calories at rest. Losing 40 pounds can reduce daily energy needs by roughly 200-300 calories, purely from having less tissue to maintain. On top of that, adaptive thermogenesis - the body's tendency to become slightly more efficient than its new size would predict - shaves off more. Meanwhile, the appetite suppression you felt at week 8 on a given dose is usually softer at week 40 on that same dose. None of that means the drug stopped working. It means the deficit that produced the loss no longer exists.

The distinction that matters: are you *maintaining* a large loss, or are you *regaining*? Those are completely different situations with completely different responses.

No, and confusing the two causes a lot of unnecessary panic. Body weight fluctuates by 2-5 pounds within a single week from water, sodium, glycogen, hormonal cycle, bowel contents, and inflammation from a hard workout. A flat or rising scale for two or three weeks is inside the noise.

A true plateau is 8-12 weeks with no downward movement in your weekly average weight *and* no change in how your clothes fit or your measurements. If either of those is still moving, you are not plateaued - you are recomposing, which is common and desirable. Our guide to [body recomposition when the scale stalls](/blog/body-recomposition-on-glp1-when-the-scale-stalls) explains how muscle gain can mask fat loss on the scale for weeks at a time.

Two habits make this easier to see. First, weigh at the same time under the same conditions - first thing in the morning, after the bathroom, before eating - and track the weekly average rather than the daily number. Second, take waist and hip measurements monthly. Waist circumference tracks visceral fat, the metabolically active fat around your organs, and it often keeps dropping when body weight is flat.

If you are in perimenopause or menopause, add another layer of patience. Hormonal fluctuation causes real water retention swings, and cycle-related weight changes of several pounds are normal. Our piece on [tracking progress beyond the scale](/blog/tracking-progress-on-glp1-in-menopause-beyond-the-scale) covers what else to measure.

Five things, and most of them cost nothing. A dose increase is a legitimate tool, but it also brings more side effects, and it is worth ruling out the fixable inputs first.

Protein. As appetite falls, protein is usually the first thing to drop, because meat and eggs are the foods that feel heaviest. Most guidance for adults losing weight lands around 1.2-1.6 g per kilogram of body weight daily, and under-eating protein accelerates muscle loss, which lowers your metabolic rate. See [how much protein you really need on GLP-1](/blog/protein-on-glp1-how-much-you-really-need).

Strength training. Two sessions a week is the standard minimum. Without it, a meaningful share of what you lose is muscle, and muscle is metabolically expensive tissue you want to keep. [Strength training on GLP-1](/blog/strength-training-on-glp1-how-to-preserve-muscle-while-losing-weight) covers the specifics.

Sleep. Short sleep raises ghrelin, lowers leptin, and increases next-day calorie intake in controlled studies. Six hours a night will fight your medication.

Alcohol. Many people find they drink less on a GLP-1, but if you have not, alcohol is calorie-dense, disinhibiting, and disruptive to sleep. It is a common and invisible contributor.

Actual intake. Not a judgment - a measurement. Appetite suppression fades at a steady dose, and portions creep back without any conscious decision. Three days of honest logging usually answers the question faster than another month of wondering.

Sometimes, and it is a reasonable next step once the basics are covered. GLP-1 medications show a dose-response relationship: higher doses generally produce more weight loss on average. In SURMOUNT-1, tirzepatide produced 15.0% loss at 5 mg and 20.9% at 15 mg over 72 weeks (NEJM 2022). If you plateaued at a middle dose and are tolerating it well, moving up is a standard clinical move.

But the ceiling is real. Once you are at the maximum approved dose, there is nowhere further to escalate, and that is where many long-term plateaus sit. Our guide to [dose escalation - when to move up and when to hold](/blog/glp1-dose-escalation-when-to-increase-and-when-to-hold) covers the timing and the tolerability trade-offs.

The second option is switching molecules. SURMOUNT-5 compared tirzepatide directly against semaglutide 2.4 mg in adults with obesity and found 20.2% versus 13.7% mean weight loss at 72 weeks (NEJM 2025). If you are plateaued on maximum-dose semaglutide, switching to tirzepatide is an evidence-supported conversation to have. The comparison is covered in detail in [tirzepatide vs semaglutide](/blog/tirzepatide-vs-semaglutide-surmount-5-head-to-head).

What a dose increase will not fix: a plateau caused by not eating enough. Under-eating on a GLP-1 is more common than people expect, and it produces fatigue, muscle loss, hair shedding, and a stubbornly flat scale. Raising the dose in that situation makes everything worse. [Eating enough on GLP-1](/blog/eating-enough-on-glp1-during-menopause-calorie-floor) is worth reading before you assume the answer is less food.

This is the question most people skip, and it deserves real consideration. A plateau at 15-20% below your starting weight is, clinically, an excellent outcome. It is more than any prior non-surgical obesity treatment reliably achieved. The health benefits that matter most - blood pressure, lipids, blood sugar, sleep apnea, joint load, and cardiovascular events - largely track with the loss you have already banked, not with the additional 10 pounds you are chasing.

In SELECT, semaglutide reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and existing cardiovascular disease, at an average weight loss of about 9.4% (Lincoff et al., NEJM 2023). That is well below what many people would consider a satisfying number, and the cardiovascular benefit was substantial.

There is also a real physical cost to pushing further. Continued aggressive deficits increase lean mass loss, and in midlife women that stacks on top of age-related and menopause-related muscle and bone loss. Our article on the [muscle loss double risk](/blog/glp1-menopause-muscle-loss-the-sarcopenia-double-risk) covers why the calculus is different after 45.

If you decide the plateau is your maintenance point, that is a plan, not a surrender - and it needs its own strategy, because stopping the medication is a separate decision with its own evidence. In SURMOUNT-4, participants who stopped tirzepatide after 36 weeks regained roughly 14% of body weight over the following year, while those who continued lost a further 5.5% (JAMA 2024). Maintenance usually means staying on some dose, not stopping.

Talk this through with your prescriber rather than deciding alone. The right answer depends on your starting point, your health markers, and what you can sustain.

Change what you are measuring. When the scale is the only feedback you get and the scale is frozen, weeks of good work register as nothing. That is a measurement problem, not a progress problem.

Pick two or three non-scale markers and track those instead. Waist circumference. How many push-ups or how much weight on a lift. Resting heart rate. How many flights of stairs before you are winded. Whether your rings and shoes fit differently. Blood pressure at home. Your next lab panel - A1C, triglycerides, ALT. These move on different timelines than body weight, and during a plateau they are often the things still improving.

Second, protect the habits from the outcome. If you only strength train when the scale rewards you, the habit dies during every stall - which is exactly when it matters most for keeping muscle. Decoupling the behavior from the number is the single most durable thing you can do.

Third, watch for the emotional turn. Plateaus are where a lot of people start restricting harder, skipping meals, or feeling like the medication has judged them. If you notice the stall pulling you toward food rules that feel punishing, that is worth naming out loud with your care team. Our piece on [weight loss guilt on GLP-1](/blog/weight-loss-guilt-on-glp1-why-you-feel-it-and-how-to-cope) covers the emotional side of this, and it is more common than most people admit.